Formulation and Characterization of Injectable Poly(dl-lactide-co-glycolide) Implants Loaded with N-Acetylcysteine, a MMP Inhibitor
- 22 September 2007
- journal article
- research article
- Published by Springer Science and Business Media LLC in Pharmaceutical Research
- Vol. 25 (3), 586-597
- https://doi.org/10.1007/s11095-007-9430-1
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Cancer Statistics, 2007CA: A Cancer Journal for Clinicians, 2007
- Reduced nonprotein thiols inhibit activation and function of MMP-9: Implications for chemopreventionFree Radical Biology & Medicine, 2006
- A 12-Month Clinical Study of LA-2585 (45.0 MG): A New 6-Month Subcutaneous Delivery System for Leuprolide Acetate for the Treatment of Prostate CancerJournal of Urology, 2006
- Polythiol-functionalized alumina membranes for mercury captureJournal of Membrane Science, 2005
- Factors affecting the degradation and drug‐release mechanism of poly(lactic acid) and poly[(lactic acid)‐co‐(glycolic acid)]Polymer International, 2004
- An eight-month clinical study of LA-2575 30.0 mg: a new 4-month, subcutaneous delivery system for leuprolide acetate in the treatment of prostate cancerUrology, 2003
- Expression of matrix metalloproteinase 1, matrix metalloproteinase 2, and matrix metalloproteinase 9 in carcinoma of the head and neckCancer, 2002
- Measurement of Hydrogen Peroxide in Biological Samples Containing High Levels of Ascorbic AcidAnalytical Biochemistry, 1998
- Crystalline oligomeric stereocomplex as an intermediate compound in racemic poly(DL‐lactic acid) degradationPolymer International, 1994
- A biodegradable injectable implant for delivering micro and macromolecules using poly (lactic-co-glycolic) acid (PLGA) copolymersJournal of Controlled Release, 1993